Resonant Capital Advisors LLC Purchases 358 Shares of Boston Scientific Co. (NYSE:BSX)

Resonant Capital Advisors LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 9.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,345 shares of the medical equipment provider’s stock after buying an additional 358 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Boston Scientific were worth $388,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Catalina Capital Group LLC raised its stake in Boston Scientific by 4.0% in the 4th quarter. Catalina Capital Group LLC now owns 6,140 shares of the medical equipment provider’s stock valued at $548,000 after acquiring an additional 236 shares during the period. S.A. Mason LLC increased its stake in shares of Boston Scientific by 7.7% in the fourth quarter. S.A. Mason LLC now owns 2,515 shares of the medical equipment provider’s stock worth $225,000 after purchasing an additional 180 shares in the last quarter. Chicago Capital LLC raised its position in shares of Boston Scientific by 1,390.4% in the fourth quarter. Chicago Capital LLC now owns 203,476 shares of the medical equipment provider’s stock valued at $18,174,000 after purchasing an additional 189,824 shares during the period. FSM Wealth Advisors LLC lifted its stake in shares of Boston Scientific by 3.0% during the 4th quarter. FSM Wealth Advisors LLC now owns 6,672 shares of the medical equipment provider’s stock valued at $655,000 after buying an additional 195 shares in the last quarter. Finally, Valley National Advisers Inc. boosted its holdings in Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 286 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.7 %

NYSE:BSX opened at $103.11 on Tuesday. The firm has a market capitalization of $151.97 billion, a P/E ratio of 85.22, a P/E/G ratio of 2.68 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average of $93.47 and a 200 day moving average of $86.33. Boston Scientific Co. has a 52 week low of $64.08 and a 52 week high of $104.25.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BSX. Citigroup boosted their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company increased their price objective on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Truist Financial lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Stifel Nicolaus increased their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $100.39.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.